Bristol-Myers Squibb Sued for $450 Million Over Drug Acquisition
Bristol-Myers Squibb Co. plotted to rip off investors in a 2016 acquisition through legal gamesmanship aimed at evading a $450 million payment, according to a lawsuit unsealed Tuesday.
Bristol Myers Squibb Announces Dividend Increase
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.IM06wodO.js
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slid 1.00% to $58.12 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.30% to 6,034.91 and Dow Jones Industrial Average DJIA falling 0.35% to 44,247.83.
Is Bristol Myers Squibb (BMY) a Great Value Stock Right Now?
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies,
Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY)
In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with
Is Bristol-Myers Squibb Stock a Millionaire Maker?
Bristol-Myers Squibb (NYSE: BMY) is the kind of stock that potentially has a lot to offer to investors looking for wealth-building investments. With that in mind, let's examine this stock's potential as a millionaire maker.
Bristol Myers A Top Socially Responsible Dividend Stock With 4% Yield
The annualized dividend paid by Bristol Myers Squibb Co. is $2.4/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 10/04/2024
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
The stock's fall snapped a two-day winning streak.
Bristol-Myers Squibb: Balancing Stability and Competition with Cautious Optimism
Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of
Justice on the Move: The Impact of 'Bristol-Myers Squibb' on FLSA Forum-Shopping
Savvy plaintiffs-side attorneys are leveraging this split to avoid bringing their FLSA collective action where the employer ...
Modern Healthcare5h
These pharma lawsuits could transform 340B
Johnson & Johnson and other pharma companies aim to change how the 340B Drug Pricing Program functions. Courts must rule if ...
Bristol Myers raises quarterly dividend 3.3% to 62c per share
Squibb announced that its Board of Directors has declared a quarterly dividend of 62c per share on the 10c par value common ...
Morningstar2d
Bristol-Myers Squibb Co
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline ...
BioSpace3d
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More
Ionis Pharmaceuticals is advancing the investigational RNA-targeted therapy olezarsen for the treatment of familial ...